Jason Amello - 28 Apr 2023 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Chief Financial Officer
Issuer ticker: CADL
Reported as of: 28 Apr 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 May 2023, 16:45:09 UTC
Prior SEC filing: 16 Mar 2023
Next SEC filing: 28 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Jason A. Amello

Key filing fact

Jason Amello filed Form 4 for Candel Therapeutics, Inc. (CADL) on 02 May 2023.

Key facts

This page summarizes Jason Amello's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 May 2023, 16:45.

Change

Previous filing in this sequence was filed on 16 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +90,000
Change %
Price: $0.000000
Shares after: 90,000
Date: 28 Apr 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,000
Exercise price: $1.29
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.